Advertisement

Topics

BiondVax Pharmaceuticals Ltd Company Profile

16:31 EDT 23rd March 2019 | BioPortfolio

BiondVax is a publicly traded (TASE: BNDX), advanced clinical stage biotech company dedicated to improving protection against influenza, with its lead product a universal influenza (flu) vaccine called M-001. Flu is the most common infectious disease, caused by countless flu strains, as the virus mutates unpredictably and frequently. Currently, seasonal flu vaccines are re-formulated each year as they only protect against 3-4 strains (those predicted to be in circulation) and pre-pandemic flu vaccines (in stockpiles) are designed to protect against 1 strain that is considered the most likely public health threat. BiondVax's universal flu vaccine is designed to protect against all A and B flu strains, present and future, seasonal and pandemic, as it triggers our immune defenses to recognize conserved and common parts of the virus.

At this point in time, BiondVax's M-001 has several unique competitive advantages: the universal flu vaccine at the most advanced stage of clinical development (4 clinical trials with 440 people); an excellent safety profile; triggers both arms of our immune defenses, cellular and humoral (antibodies); active without the need for an adjuvant; easily, quickly and cheaply manufactured in only 6-8 weeks (current vaccines take 6-8 months); can be produced year-round and stockpiled as its composition does not change; and finally, M-001 has two indications, as a universal flu vaccine and as an enhancer of current seasonal/pandemic flu vaccines. Of note, this second indication provides an alternative pathway for clinical development, regulatory approval and commercialization of M-001 and is a new approach to improving pandemic preparedness.

BiondVax Pharmaceuticals, a publicly-traded company (TASE: BNDX) located in the Weizmann Science Park in Ness-Ziona (Israel), is dedicated to the development of a novel Universal Influenza Vaccine. BiondVax's Universal Flu Vaccine is based on research carried out over a period of 20 years by Weizmann Institute Professor Ruth Arnon, who heads the company's Scientific Advisory Board. Professor Arnon is well-known for her part in the development of Copaxone®, a blockbuster drug for the treatment of multiple sclerosis.

The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, Israel, for developing, manufacturing and commercializing this innovative flu vaccine.

BiondVax’s team of 14 includes scientists, technicians, researchers, and administrative staff. The company’s state-of-the-art GMP facility in Ness-Ziona houses its laboratories, production facilities and offices.

To date, BiondVax has raised a total of over US$16 million. Of this amount, approximately $4.1 million was raised from private investors and $2.0 million from the Israeli Office of the Chief Scientist. In June 2007, BiondVax started trading on the Tel-Aviv Stock Exchange (TASE: BNDX), raising an additional ~$3 million. In December 2009, BiondVax executed a follow-on offering on the Tel-Aviv Stock Exchange, raising an additional $5.3 million.  In 2010, BiondVax concluded an agreement with Yorkville Advisors for a standby equity facility of $7m - $15m – using this facility, BiondVax raised $1.25m in November 2010.

Location

Science Park, 14 Einstein Street
PO Box 4143
Ness Ziona
74140
Israel

Contact

Phone: +972 8 930 2529
Fax: +972 8 930 2531
Email: info@biondvax.com


News Articles [390 Associated News Articles listed on BioPortfolio]

BiondVax Pharmaceuticals Ltd: Wayne Rudolph explains their focus on development of a Universal Influenza vaccine.

In this episode of PharmaTelevision News Review, filmed at BIO 2011, Fintan Walton talks to Wayne Rudolph, Vice President of Corporate Development of BiondVax Pharmaceuticals Ltd.

BiondVax Pharmaceuticals Ltd BVXV Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 14122018] Prices from USD $250

SummaryBiondVax Pharmaceuticals Ltd BiondVax is a biopharmaceutical company that develops universal flu vaccine. The company's lead product M001 is a synthetic peptidebased protein that provides prote...

BiondVax Pharmaceuticals Ltd BVXV Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250

SummaryBiondVax Pharmaceuticals Ltd BiondVax is a biopharmaceutical company that develops universal flu vaccine. The company's lead product M001 is a synthetic peptidebased protein that provides prote...

MGC Pharmaceuticals - MGC Derma sale completed

Edison Investment Research - Pharmaceuticals & healthcare - MGC Pharmaceuticals: Key milestones for MGC Pharmaceuticals in 2019 include the launch of CannEpil sales in Australia, finalising contrac...

AMAG Pharmaceuticals to Acquire Perosphere Pharmaceuticals

AMAG Pharmaceuticals said today it has agreed to acquire Perosphere Pharmaceuticals for up to $415 million, in a deal that the buyer said will expand its pipeline, and especially its presence in hemat...

InMed Pharmaceuticals - Entering the clinic by the end of the year

Edison Investment Research - Pharmaceuticals & healthcare - InMed Pharmaceuticals: InMed recently reported results for the second quarter of FY19 and is on track to bring INM-750 for epidermolysis ...

Checkmate Pharmaceuticals Appoints Barry Labinger President & CEO

Barry Labinger has joined Checkmate Pharmaceuticals as president and CEO, the Cambridge, MA, company announced Wednesday. Labinger comes to the cancer drug developer from Biothera Pharmaceuticals, whe...

Telix Pharmaceuticals Limited: Telix Pharmaceuticals Acquires Advanced Nuclear Medicine Ingredients (ANMI) SA

MELBOURNE, Australia, BRUSSELS and LIÈGE, Belgium, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) ("Telix", the "Company"), a clinical-stage biopharmaceutical company foc.....

Drugs and Medications [0 Results]

None

PubMed Articles [143 Associated PubMed Articles listed on BioPortfolio]

Swimming activity in zebrafish larvae exposed to veterinary antiparasitic pharmaceuticals.

Veterinary antiparasitic pharmaceuticals have been detected in surface waters and several of these pharmaceuticals act on the nervous system on the target organisms implying that neurological effects ...

Insight into the distribution of pharmaceuticals in soil-water-plant systems.

Pharmaceuticals in agricultural soils originating from irrigation with treated wastewater and land-applied biosolids can enter field crops. However, little is known about the role of pore water in pla...

U.S. Emergency Department Visits Resulting From Nonmedical Use of Pharmaceuticals, 2016.

National data on morbidity from nonmedical use of pharmaceuticals are limited. This study used nationally representative, public health surveillance data to characterize U.S. emergency department visi...

Chiral pharmaceuticals: Environment sources, potential human health impacts, remediation technologies and future perspective.

Chiral pharmaceuticals (CPs), including non-steroid anti-inflammatory drugs (NSAIDs), β-blockers and some herbicide and pesticides, are widely used in aquaculture, clinical treatment and many other f...

Assessment of 83 pharmaceuticals in WWTP influent and effluent samples by UHPLC-MS/MS: Hourly variation.

The removal efficiency of pharmaceuticals in wastewater treatment plants (WWTPs) is variable and some of these compounds pass these plants almost intact and others presenting a removal efficiency clos...

Clinical Trials [231 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic®20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sep...

Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic 20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sepa...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Cilostazol 50 mg Tablets Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEV...

Companies [1354 Associated Companies listed on BioPortfolio]

BiondVax Pharmaceuticals Ltd.

BiondVax Pharmaceuticals Ltd

BiondVax is a publicly traded (TASE: BNDX), advanced clinical stage biotech company dedicated to improving protection against influenza, with its lead product a universal influenza (flu) vaccine cal...

Maelor Pharmaceuticals Ltd.

Maelor is a publicly listed (AIM:MLR) specialist critical care pharmaceuticals and devices company. The Company has developed an expertise in bringing both pharmaceuticals and devices to the market as...

Excaliard Pharmaceuticals, Inc.

Excaliard Pharmaceuticals, Inc., is a venture capital-funded biotechnology company founded in 2007 focused on the development and commercialization of novel and innovative drugs for the amelioration o...

Serenity Pharmaceuticals

Founded in 2007 and located in Milford, Pennsylvania, Serenity Pharmaceuticals is focused on developing products that address urinary conditions that impact the health and well-be...

More Information about "BiondVax Pharmaceuticals Ltd" on BioPortfolio

We have published hundreds of BiondVax Pharmaceuticals Ltd news stories on BioPortfolio along with dozens of BiondVax Pharmaceuticals Ltd Clinical Trials and PubMed Articles about BiondVax Pharmaceuticals Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BiondVax Pharmaceuticals Ltd Companies in our database. You can also find out about relevant BiondVax Pharmaceuticals Ltd Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Influenza
Influenza or 'flu' is a respiratory illness associated with infection by influenza virus. Symptoms frequently include headache, fever, cough, sore throat, aching muscles and joints. There is a wide spectrum of severity of illness ranging from min...

Swine Flu - H1N1 influenza - H7N9
Swine flu is the common name given to a relatively new strain of influenza (flu) that caused a flu pandemic in 2009-2010. It is also referred to as H1N1 influenza (because it is the H1N1 strain of virus). The H1N1 flu virus will be one of the main vi...


Corporate Database Quicklinks



Searches Linking to this Company Record